Patient Disease:
Any requiring treatment with doxorubicin chemotherapy
Study Name:
Dogs Scheduled to Receive Doxorubicin Chemotherapy
Purpose of the study:
- Multicenter, randomized, placebo-controlled clinical trial to evaluate the effectiveness of transdermal ondansetron for the prevention of nausea and vomiting in dogs undergoing chemotherapy with doxorubicin
Eligibility:
- Body weight: ≥ 5.0 kg
- The dog is at least 6 months of age
- Chronic conditions other than cancer should be stabilized for at least 3 months
- Dog is undergoing chemotherapy with doxorubicin at any point in their chemotherapeutic regimen
- The Veterinary Investigator will determine if your pet meets other eligibility criteria and may enroll in the study
- Pets must come to CSU for all visits related to the clinical trial
Owner Participation/Commitment:
- Eligible dogs will receive doxorubicin chemotherapy and then be treated with investigational product or control product for 7 days.
- Owners must monitor their dogs for the 7 days of treatment and return on days 8-10
- Owners will be required to document study associated observations throughout the treatment period.
- In multi-animal households, the owner is able to attribute any nausea and vomiting to the dog enrolled in the study.
- Dogs with frequent vomiting will be rescued with an approved anti-emetic.
Funding:
- This is a fully funded study
If you have further questions about any of our clinical trials, please submit an online consult form. Your consult will then be directed to our trials team. Requests are typically returned within 5 business days.